13.67
4.51%
0.59
プレマーケット:
13.43
-0.24
-1.76%
前日終値:
$13.08
開ける:
$13.21
24時間の取引高:
1.39M
Relative Volume:
0.72
時価総額:
$1.17B
収益:
$139.71M
当期純損益:
$-209.36M
株価収益率:
-4.6182
EPS:
-2.96
ネットキャッシュフロー:
$-160.60M
1週間 パフォーマンス:
+8.49%
1か月 パフォーマンス:
+4.51%
6か月 パフォーマンス:
-40.77%
1年 パフォーマンス:
-33.90%
Syndax Pharmaceuticals Inc Stock (SNDX) Company Profile
名前
Syndax Pharmaceuticals Inc
セクター
電話
781-419-1400
住所
35 GATEHOUSE DRIVE, WALTHAM, MA
SNDX を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
SNDX
Syndax Pharmaceuticals Inc
|
13.67 | 1.17B | 139.71M | -209.36M | -160.60M | -2.96 |
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Syndax Pharmaceuticals Inc Stock (SNDX) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2024-10-24 | 開始されました | UBS | Buy |
2024-06-28 | 開始されました | Jefferies | Buy |
2024-01-31 | ダウングレード | Scotiabank | Sector Outperform → Sector Perform |
2023-12-22 | 開始されました | Mizuho | Buy |
2023-10-25 | 開始されました | BofA Securities | Buy |
2023-10-11 | 開始されました | Goldman | Buy |
2023-07-27 | 開始されました | Scotiabank | Sector Outperform |
2023-07-11 | 開始されました | Guggenheim | Buy |
2023-04-17 | 再開されました | BTIG Research | Buy |
2023-01-31 | 開始されました | Stifel | Buy |
2023-01-03 | 開始されました | JP Morgan | Overweight |
2022-07-28 | 再開されました | B. Riley Securities | Buy |
2022-04-11 | 開始されました | H.C. Wainwright | Buy |
2022-02-15 | 開始されました | Goldman | Buy |
2021-06-04 | 再開されました | Robert W. Baird | Outperform |
2021-05-25 | 開始されました | Citigroup | Buy |
2021-02-18 | 開始されました | B. Riley Securities | Buy |
2020-12-03 | 開始されました | Stifel | Buy |
2020-05-22 | アップグレード | Citigroup | Neutral → Buy |
2020-05-22 | ダウングレード | H.C. Wainwright | Buy → Neutral |
2020-05-18 | ダウングレード | Citigroup | Buy → Neutral |
2020-05-11 | 繰り返されました | H.C. Wainwright | Buy |
2020-03-04 | 開始されました | Barclays | Overweight |
2020-01-13 | 繰り返されました | H.C. Wainwright | Buy |
2019-03-08 | 繰り返されました | H.C. Wainwright | Buy |
2019-01-04 | 開始されました | Robert W. Baird | Outperform |
2018-01-05 | 開始されました | B. Riley FBR, Inc. | Buy |
2017-03-16 | 開始されました | FBR & Co. | Outperform |
2017-03-02 | 開始されました | Instinet | Buy |
2016-10-07 | 開始されました | Guggenheim | Buy |
2016-03-28 | 開始されました | Citigroup | Buy |
2016-03-28 | 開始されました | JMP Securities | Mkt Outperform |
2016-03-28 | 開始されました | Morgan Stanley | Overweight |
すべてを表示
Syndax Pharmaceuticals Inc (SNDX) 最新ニュース
Syndax Stock Looks Tantalizing, But Looks Can Be Deceptive (NASDAQ:SNDX) - Seeking Alpha
Syndax Pharmaceuticals (FRA:1T3) Net-Net Working Capital : €3.67 (As of Sep. 2024) - GuruFocus.com
How the (SNDX) price action is used to our Advantage - Stock Traders Daily
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Short Interest Update - MarketBeat
Syndax Pharmaceuticals (FRA:1T3) Price-to-Operating-Cash-Fl - GuruFocus.com
Syndax Pharmaceuticals (FRA:1T3) ROE % Adjusted to Book Val - GuruFocus.com
Assenagon Asset Management S.A. Has $27.29 Million Stock Position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat
Incyte, Syndax get FDA okay for 9 mg, 22 mg Niktimvo vials - MSN
Incyte's and Syndax's Graft Disease Treatment Niktimvo Gets FDA Approval for Vial Sizes - Marketscreener.com
Incyte and Syndax Announce U.S. Food and Drug Administration (FDA) Approval of Niktimvotm (axatilimab-csfr) 9 mg and 22 mg Vial Sizes - Lelezard
FDA Approves Niktimvo: Breakthrough Treatment for Chronic GVHD Shows 75% Response Rate - StockTitan
Syndax Pharmaceuticals' SWOT analysis: stock poised for growth amid AML breakthroughs - Investing.com Nigeria
Syndax Pharmaceuticals (FRA:1T3) Cash From Discontinued Inv - GuruFocus.com
Syndax Pharmaceuticals' SWOT analysis: stock poised for growth amid AML breakthroughs By Investing.com - Investing.com South Africa
SNDX stock touches 52-week low at $12.38 amid market challenges - Investing.com Nigeria
Syndax Pharmaceuticals (NASDAQ:SNDX) Reaches New 1-Year LowHere's Why - MarketBeat
Syndax Achieves Dual FDA Approvals for Breakthrough Cancer & GVHD Treatments in Major Growth Milestone - StockTitan
Syndax Pharmaceuticals (FRA:1T3) Other Current Receivables : €4.23 Mil (As of Sep. 2024) - GuruFocus.com
Investing in Syndax Pharmaceuticals (NASDAQ:SNDX) five years ago would have delivered you a 53% gain - Yahoo Finance
Syndax Pharmaceuticals' SWOT analysis: stock poised for growth amid challenges - Investing.com India
Syndax Pharmaceuticals (NASDAQ:SNDX) Given New $16.00 Price Target at Scotiabank - MarketBeat
Kuehn Law Encourages Investors of Syndax Pharmaceuticals, Inc. to Contact Law Firm - The Eastern Progress Online
Where are the Opportunities in (SNDX) - Stock Traders Daily
Syndax Pharmaceuticals CEO to Present at J.P. Morgan Healthcare Conference 2025 - StockTitan
Jefferies maintains Buy rating on Syndax stock with $43 target By Investing.com - Investing.com Nigeria
Syndax Pharmaceuticals Awards 123,100 Stock Options to New Hires in Growth Initiative - StockTitan
Syndax Pharmaceuticals (NASDAQ:SNDX) Shares Up 4.1%What's Next? - MarketBeat
Stifel Financial Corp Purchases Shares of 16,976 Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - Defense World
Analysts Set Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Price Target at $36.90 - MarketBeat
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World
SNDX stock touches 52-week low at $12.75 amid market challenges - Investing.com Canada
Syndax Pharmaceuticals (NASDAQ:SNDX) Sets New 1-Year LowWhat's Next? - MarketBeat
Syndax Pharmaceuticals, Inc. Announces Cessation of Catherine Madigan as Chief Medical Officer - Marketscreener.com
Geode Capital Management LLC Boosts Holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - Defense World
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Shares Bought by Geode Capital Management LLC - MarketBeat
Syndax Pharmaceuticals (NASDAQ:SNDX) Shares Down 2.6%Should You Sell? - MarketBeat
Barclays PLC Purchases 110,535 Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat
Syndax Pharmaceuticals CMO position eliminated By Investing.com - Investing.com Canada
Syndax Pharmaceuticals CMO position eliminated - Investing.com
Syndax Pharmaceuticals' SWOT analysis: stock poised for growth amid FDA approvals - Investing.com
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) for Potential Breaches of Fiduciary Duty By Its Board of Directors - cnhinews.com
Franklin Resources Inc. Has $34.95 Million Stock Position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat
SNDX stock touches 52-week low at $13.26 amid market challenges - Investing.com Canada
State Street Corp Increases Stock Position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat
Fmr LLC Has $948,000 Holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - Defense World
Syndax Pharmaceuticals' SWOT analysis: biotech stock poised for growth amid challenges - Investing.com India
Syndax Pharmaceuticals Inc (SNDX) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):